Advanced cell and gene therapies require novel pricing and reimbursement models
Jorge Conde · Healthcare Has Left the Building · Apr 29, 2020 · at 18:09
This episode carries Jorge Conde's own address, with nobody on the show putting questions to them. It still counts as said, and it is kept out of every score on their page.
Jorge Conde, General Partner on the a16z Bio Fund, explains the infrastructure requirements for scalable delivery of cell and gene therapies.
0:00 / 0:26exact quote · 26.9s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“If we're gonna make this widely accessible to patients that need them, it's gonna have to be affordable. So we'll need new models for how pharmaceutical companies charge for this, and we're seeing early days of this. We're going to need new models for how payers are able to pay for this and take on the associated costs with providing this therapy. And then to connect those two things, we're of course going to need the models and the technology to monitor for efficacy, to make sure that the therapies are doing what they need to be doing to justify the costs.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Jorge Conde
Conde: AI has not yet compressed biotech clinical trial timelines
“We still haven't seen, and I think it's coming, but it hasn't happened yet. We haven't seen artificial intelligence or other technologies massively compress the amount of time it takes us to do the clinical development, the clinical trials, the enrollment of p…”
Novartis's one-time gene therapy for spinal muscular atrophy costs $2.1 million
“You know, in the case of treating a baby that had, you know, something like somatic muscular atrophy that would have otherwise died, a one and done gene therapy from Novartis, this is a therapy that's worth about, it's cost about 2.1 million dollars, effective…”
Conde: Engineering principles make later drug programs more valuable than earlier ones
“The second drug is more valuable than the first if you're using engineering principles, because what you learn from example one sort of imbues value to example two and so on and so forth.”
Conde: Biology is transforming from experimental science into an engineered discipline
“It's really just one subset of what we think is the broader theme here, which is the shift away from biology being primarily an empirical or an experimental science to becoming more of an engineered discipline.”
Conde: Engineering principles make subsequent drug candidates more valuable than earlier ones
“But in your world, in the world you're describing, this engineering world, it's actually the reverse is true. That the second drug is more valuable than the first if you're using engineering principles, because what you learn from example one sort of imbues va…”
Conde: Platforms focused solely on target discovery struggle to capture value
“And so if your platform is to identify novel targets, it's going to actually be very hard. That's sort of the end of the line for what your technology can do. It's really hard to capture value there. And certainly hard to get that from a collaboration standpoi…”